Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. - Wikidata - wikimedia - TriplyDB

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

http://www.wikidata.org/entity/Q36195450

about

In vitro human cell line models to predict clinical response to anticancer drugs Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.Olaparib: first global approval.Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP)Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer.PARP inhibitors: the journey from research hypothesis to clinical approval.CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions

P2860

Q27000665-0EDB8A1F-C569-4B6A-A771-ABF48FCF45E4 Q27853018-EBBC0CD9-529B-4B46-8A4E-BA32BD3B4754 Q33429801-2C140C70-BE7E-4671-8DA1-523C77B4369D Q34249365-FDBC14E6-2472-4215-B9A8-E84C97CD1261 Q35764901-374799EC-9C1C-4F13-A815-0C2DD28F7E90 Q36245791-764A4A92-26CA-40A9-865A-669C9DFB8690 Q37269217-197D55F0-99E9-4024-8CA6-9E1DB879227F Q37584321-982C47B2-763A-471F-B6D1-AD618A681615 Q37644990-C36A40F2-7D80-44E3-AD44-44FDA40DB9C0 Q37704344-251DF9FD-384D-4980-BC19-3215A84C34C2 Q38330356-735ACD12-2133-488F-BCB3-1717D63CCBB7 Q38840443-5431E36C-4211-4AA0-BEB5-607C854E5FE8 Q38954348-0D730F9A-2FB3-4D5A-B43F-7E17F9D7A08A Q38981220-537CE4C2-833F-46C6-8D05-2254550FB1E8 Q39375196-DC309874-4660-4CF1-AFB6-0DAE35602522 Q41092671-714A54F7-3FAD-4151-9591-1E05F3431D71 Q41276800-A01CCAB4-ED94-4318-960C-554DBB4552FA Q41527706-F765BA3E-9968-46EF-ADC1-439E0821E39F Q44085049-DEB02B60-C62A-4643-957F-56CF6E32288C Q47156447-97AD6E97-989D-4743-A463-C22FBBEA3C36 Q47621328-297AF556-4ADB-4C18-9DE4-E3ADC1673EE2 Q53682668-7C483888-F810-4CD6-BD18-B0C55296EC14 Q59084697-11ABB552-66FA-4F84-84B2-266BF2134D89

P2860

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

http://www.wikidata.org/entity/Q36195450

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Cross-platform pathway-based a ...... o the PARP inhibitor olaparib.

@ast

Cross-platform pathway-based a ...... o the PARP inhibitor olaparib.

@en

type

label

Cross-platform pathway-based a ...... o the PARP inhibitor olaparib.

@ast

Cross-platform pathway-based a ...... o the PARP inhibitor olaparib.

@en

prefLabel

Cross-platform pathway-based a ...... o the PARP inhibitor olaparib.

@ast

Cross-platform pathway-based a ...... o the PARP inhibitor olaparib.

@en

P1433

Q36195450-8A7C54EC-40A2-4A73-9A40-5812DB36680B

P1476

Q36195450-9D991006-C174-4A14-8CE2-632DC1092C0D

P2093

Q36195450-2FC5A382-4BCE-4314-B36D-917A388A1068

Q36195450-403C1534-1990-4FEF-88AA-4F3963178B3F

Q36195450-431F862D-29EC-41F7-875C-D6F954C5DC08

Q36195450-49C19B03-0FF6-481D-96ED-C051B52C6546

Q36195450-79D5BD20-516A-4CCE-ABB3-4F214F48221F

Q36195450-B8A47259-24F7-4B38-B05A-8B174113FEB8

Q36195450-BF0E87BC-C671-4632-9EEE-2A8FA352381C

Q36195450-C7C5F740-6ED4-4C5C-A42E-F006E05ECDE1

Q36195450-CB408613-2AC6-44A3-85C6-0EE97E1D70D7

Q36195450-EC0C0C9B-D29A-4C47-9A7C-58910758E47E

P2860

Q36195450-04E85ADA-9141-4014-80B9-B89A207354ED

Q36195450-08A09B41-BDB5-41E1-88EF-556C271C2DB5

Q36195450-0DBB0CBF-915F-4390-93AE-79D034858051

Q36195450-0DCFD016-0C09-4110-847F-E97BFA9E8D16

Q36195450-114731F1-5775-46FE-B2CA-CB92B76171F6

Q36195450-12E537E0-6F0C-467D-A132-D54F30019B90

Q36195450-13D74AE6-74A8-40C4-B85A-85A97C07BCFF

Q36195450-1448931B-1E02-4C6B-A542-8ED46DA4C340

Q36195450-1599478A-FF19-4067-8215-04C044B158A4

Q36195450-2CE5FDC0-FC0E-4F30-AD28-C2F0A94ACC90

P2888

Q36195450-F2818E2E-FCCB-4BA4-A0E3-4C60A218BE09

P304

Q36195450-123C4070-FE15-4FEF-BEB9-4CC5BC30EFA8

P31

Q36195450-0D8CA7C2-8341-4D40-B0AA-14F1905BE27B

P356

Q36195450-DCA6B9F5-80E9-4E94-A035-9DF59A73D615

P407

Q36195450-2AA95CEA-1671-4808-B109-5BD0B53AB33B

P433

Q36195450-41D1D29B-6129-49D5-9A71-6C8871264195

P478

Q36195450-D62B594C-9E4A-43E8-9891-F4174C54CE36

P50

Q36195450-30438502-28C4-4FDF-B355-80DF5B6C796D

Q36195450-3C6FF18D-F15B-42FC-ADD2-31DB56B3555D

Q36195450-9524F0D4-253B-4D3B-8686-C085A9F122F1

Q36195450-A7A45EB9-C805-4EF1-B634-CDB65E361095

Q36195450-E97B620A-972D-437A-939D-6B0D92AF5FB1

P577

Q36195450-27F0230B-8828-4B4F-8EFA-9EAA0B01890E

P5875

Q36195450-4032D890-EF0E-4060-B895-FE170314DBB9

P698

Q36195450-2E22DB4F-182D-4879-907B-C858A2BA5FF9

P932

Q36195450-85F0FF87-9F73-4125-A57B-887253F6FEE0

P356

S10549-012-2188-0

P1433

Breast Cancer Research and Treatment

P1476

Cross-platform pathway-based a ...... o the PARP inhibitor olaparib.

@en

P2093

Anneleen Daemen

http://www.w3.org/2001/XMLSchema#string

Denise M Wolf

http://www.w3.org/2001/XMLSchema#string

James E Korkola

http://www.w3.org/2001/XMLSchema#string

Jessica R Frankum

http://www.w3.org/2001/XMLSchema#string

Joe W Gray

http://www.w3.org/2001/XMLSchema#string

Lakshmi R Jakkula

http://www.w3.org/2001/XMLSchema#string

Laura J van't Veer

http://www.w3.org/2001/XMLSchema#string

Nicholas J Wang

http://www.w3.org/2001/XMLSchema#string

Paul T Spellman

http://www.w3.org/2001/XMLSchema#string

Rachel Brough

http://www.w3.org/2001/XMLSchema#string

P2860

DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization

KEGG for representation and analysis of molecular networks involving diseases and drugs

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

The DNA Damage Response: Making It Safe to Play with Knives

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

PARP inhibitors stumble in breast cancer

Germline mutations in RAD51D confer susceptibility to ovarian cancer

Synthetic lethality--a new direction in cancer-drug development

P2888

s10549-012-2188-0

P304

505-517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-012-2188-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

135

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Reis-Filho

Rachael Natrajan

Christopher J Lord

P577

2012-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230638716

http://www.w3.org/2001/XMLSchema#string

P698

22875744

http://www.w3.org/2001/XMLSchema#string

P932

3429780

http://www.w3.org/2001/XMLSchema#string